Thinking of switching from Mounjaro 12.5mg to Wegovy?

Why people consider switching at this stage, and what the decision really involves

By 12.5mg, most people on Mounjaro have been in treatment for at least six months. That is long enough to have a clear view of how your body has responded: weight lost, side effects experienced, how well the injections fit your weekly routine. Switching to Wegovy at this point usually comes down to one of three things: access and cost, clinical guidance, or curiosity about whether a different drug would suit you better.

The honest starting point is that these medicines work differently. Mounjaro (tirzepatide) activates two receptors (GIP and GLP-1) while Wegovy (semaglutide) targets GLP-1 alone. That distinction shapes the trial evidence, the side-effect profile, and what a prescriber weighs up when you ask about switching. The full comparison of Wegovy and Mounjaro covers this in detail, but the short version is: tirzepatide's dual action is associated with greater average weight reduction in head-to-head data, specifically in the SURMOUNT-5 trial published in the New England Journal of Medicine (2025).

None of that makes Wegovy the wrong choice for any individual. If you've had persistent GI side effects at higher Mounjaro doses, or your prescriber has a clinical reason to recommend semaglutide, the evidence still supports Wegovy as an effective treatment. What it does mean is that a switch at 12.5mg deserves a proper clinical conversation, not a like-for-like assumption. Our page on moving from 12.5mg Mounjaro to Wegovy walks through that conversation in detail if you want to read ahead before speaking to a prescriber.

Dose equivalence: why 12.5mg Mounjaro doesn't map neatly to a Wegovy number

This is where a lot of confusion starts. Patients reasonably ask: if I'm on 12.5mg of Mounjaro, which Wegovy dose matches that? The answer is that the doses are not comparable on a milligram basis, the two molecules are structurally distinct, measured in entirely different ways, and titrated along separate schedules.

Mounjaro runs from 2.5mg up to 15mg, typically stepped in 4-week increments; Wegovy moves from 0.25mg through to 2.4mg as its standard maintenance dose, with a newer 7.2mg pen approved by the MHRA in April 2026 for adults with a BMI of 30 or above. A useful resource if you want to explore this mapping in more depth is our page on Mounjaro-to-Wegovy dose conversion. The general clinical principle, where switching is appropriate, is to restart Wegovy at a low dose and titrate up as your prescriber directs, not to jump to a 'matching' maintenance dose.

For context on how the lower end of the Mounjaro ladder compares to Wegovy's starting point, our page on Wegovy 0.25mg vs Mounjaro 2.5mg explains why the starter-dose comparison matters clinically. If you're thinking about a switch partway up the titration (say from 7.5mg rather than 12.5mg) the considerations are slightly different and covered on our 7.5mg switching page.

The practical upshot: your prescriber will not simply convert a dose. They will assess where you are, whether a switch is clinically sensible, and what starting point on Wegovy is appropriate for you specifically.

How the trial evidence and cost compare at this point in treatment

At 12.5mg you are near the top of the Mounjaro dose ladder. The clinical trial evidence at the highest doses (from SURMOUNT-1, in which tirzepatide produced average weight reductions of around 20–21% at 15mg over 72 weeks) suggests the treatment is performing well if you are tolerating it. Wegovy's STEP 1 trial, also 68–72 weeks in duration, reported average weight loss of around 15% at 2.4mg, as documented by NHS guidance on semaglutide. The newer 7.2mg Wegovy dose narrowed that gap in trials, reaching approximately 20.7% average weight loss, though direct head-to-head data at that strength are still limited.

Cost is a genuine factor for many people, and we address the pricing picture plainly on our page about why Wegovy is often cheaper than Mounjaro. Mounjaro's UK list price rose significantly from September 2025, and higher doses cost more; Wegovy's 2.4mg maintenance dose has typically sat at a lower private price point. Whether that price difference makes a switch worthwhile is a question only you and your prescriber can answer, it depends on how much weight you still want to lose, what side effects you are managing, and how far into treatment you are.

The table below gives a factual side-by-side view of the two medicines at the points most relevant to a switch from Mounjaro 12.5mg.

How to make the switch safely, and what our prescribers look for

If you are seriously considering moving from Mounjaro 12.5mg to Wegovy, the first step is a clinical review, not an internet search. A prescriber will want to know how long you have been on 12.5mg, what weight loss you have achieved, how you are tolerating the dose, and what your health picture looks like now compared with when you started. If you started on Mounjaro with us and want to discuss switching, the aftercare team is the right first contact, reach us via our contact page.

If you are coming from another provider and have evidence of your current dose and treatment history, our prescribers review transfer patients with the same clinical rigour as new consultations. You can read about our clinical approach on our prescriber profile page, and a broader overview of the treatments we offer is at our weight-loss treatments overview. Payday timing, a planned holiday, a long bank-holiday weekend, these are legitimate things to flag when you start a consultation, because they affect when you need your first delivery and whether the timing of a restart works for you. Worth raising early.

Whichever direction you are considering, the consultation is free and carries no obligation. Which medicine suits you is a clinical decision our prescribers make with you, based on your health and your goals, not on which headline trial figure looks more impressive.